The effect of coenzyme Q10 supplementation on depressive symptoms and anxiety: a systematic review and meta-analysis of randomized controlled trials
- PMID: 40833470
- DOI: 10.1007/s00228-025-03904-9
The effect of coenzyme Q10 supplementation on depressive symptoms and anxiety: a systematic review and meta-analysis of randomized controlled trials
Abstract
Background: Anxiety and depression are major global health concerns that can manifest as primary disorders or as comorbid symptoms alongside other medical conditions. Due to the troubling side effects and treatment resistance associated with conventional pharmacological interventions, therapeutic agents that target oxidative stress and inflammation, such as CoQ10, have been considered.
Objective: To quantitatively evaluate the effect of CoQ10 on symptoms of depression and anxiety across different clinical populations.
Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and comprehensively searched relevant databases up to March 2025. The primary outcomes were depression and anxiety symptoms measured by different validated scales. We estimated pooled effect estimates using standardized mean differences (SMDs) and applying random-effects models.
Results: We identified seven small trials with up to 400 patients meeting the eligibility criteria, of which six studies were included in the meta-analysis. CoQ10 demonstrated significant improvement in depression severity compared to placebo in trials using the Montgomery-Åsberg Depression Rating Scale (MADRS) 6-8 weeks after treatment initiation (3 trials, 158 patients, std. mean difference [95% CI] -0.97 [-1.49, -0.45]), and at low daily doses (3 trials, 193 patients, -0.84 [-1.54, -0.14]). No significant effects were observed in trials using the Beck Depression Inventory (BDI) (3 trials, 146 patients, -0.12 [-0.68, 0.43]). Regarding anxiety severity, only two small studies were analyzed, and no statistically significant reduction was observed with CoQ10 (101 patients, -0.28 [-0.70, 0.13]).
Conclusion: Our analysis provided limited evidence that CoQ10 may improve depressive symptoms when administered in low doses (100-200 mg/day) and for short durations (6-8 weeks). More data is needed for a reliable assessment of the effects of Coenzyme Q10 on both depression and anxiety.
Keywords: Anxiety; CoQ10; Coenzyme Q10; Depression.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval and Consent to Participation: N/A. Consent for Publication: N/A. Competing interests: The authors declare no competing interests.
Similar articles
-
Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2014;2014(12):CD010405. doi: 10.1002/14651858.CD010405.pub2. Epub 2014 Dec 4. Cochrane Database Syst Rev. 2014. PMID: 25474484 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Vortioxetine for depression in adults.Cochrane Database Syst Rev. 2017 Jul 5;7(7):CD011520. doi: 10.1002/14651858.CD011520.pub2. Cochrane Database Syst Rev. 2017. PMID: 28677828 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Apr 19;4:CD011535. doi: 10.1002/14651858.CD011535.pub4. PMID: 31917873 Free PMC article. Updated.
References
-
- Neergheen V et al (2017) Coenzyme Q10 in the treatment of mitochondrial disease. J Inborn Errors Metab Screen 5:232640981770777. https://doi.org/10.1177/2326409817707771 - DOI
-
- Sood B, Patel P, Keenaghan M (2025) Coenzyme Q10. In: StatPearls. StatPearls Publishing, Treasure Island (FL). [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK531491/ . Accessed 10 Apr 2025
-
- Mantle D, Dybring A (2020) Bioavailability of coenzyme Q10: an overview of the absorption process and subsequent metabolism. Antioxidants 9(5):386. https://doi.org/10.3390/antiox9050386 - DOI - PubMed - PMC
-
- Bentinger M, Tekle M, Dallner G (2010) Coenzyme Q - biosynthesis and functions. Biochem Biophys Res Commun 396(1):74–79. https://doi.org/10.1016/j.bbrc.2010.02.147 - DOI - PubMed
-
- Clemente-Suárez V et al (2023) Mitochondria and brain disease: a comprehensive review of pathological mechanisms and therapeutic opportunities. Biomedicines 11(9):2488. https://doi.org/10.3390/biomedicines11092488 - DOI - PubMed - PMC
Publication types
LinkOut - more resources
Full Text Sources
Research Materials